Please upgrade your browser.
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
Researchers in California may have taken a big step in the fight to end renal cancer.
We list hundreds of Clinical Trials about "Oxford Biomedica TroVax trialled cancer centre" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
The risk of heart problems is more than five times greater in survivors of childhood cancer according to The Daily Telegraph. The newspaper said new research found that the risk was still high 30 years after they had beaten their cancer.
Proteomic analysis in clear cell renal cell carcinoma : identification of differentially expressed protein by 2-D DIG...
Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors...
Researchers have made exciting steps forward in the number of treatment options for advanced kidney cancer.
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation.
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics
The company is developing three drug candidates: iSONEP™ is being studied in a Phase 2 trial in wet AMD patients; ASONEP™ is being studied in a Phase 2 trial in renal cell carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.
AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma, Inc. (ALPMY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review tivozanib on May 2, 2013.
|Powered by NeonCRM|